MR13A9 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uremic Pruritus

Conditions

Uremic Pruritus

Trial Timeline

Feb 1, 2019 → Oct 22, 2019

NCT ID

NCT03802617

About MR13A9 + Placebo

MR13A9 + Placebo is a phase 2 stage product being developed by Kissei Pharmaceutical for Uremic Pruritus. The current trial status is completed. This product is registered under clinical trial identifier NCT03802617. Target conditions include Uremic Pruritus.

What happened to similar drugs?

0 of 7 similar drugs in Uremic Pruritus were approved

Approved (0) Terminated (0) Active (7)

🔄CrovalimabChugai PharmaceuticalPhase 3

🔄EculizumabAstraZenecaPhase 3

🔄IptacopanNovartisPhase 3

🔄Iptcaopan 200 mgNovartisPhase 3

🔄IptacopanNovartisPhase 3

🔄MR13A9 + PlaceboKissei PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04711603	Phase 3	Completed	Jan 16, 2021	Sep 26, 2022	Uremic Pruritus
NCT03802617	Phase 2	Completed	Feb 1, 2019	Oct 22, 2019	Uremic Pruritus

Competing Products

15 competing products in Uremic Pruritus

See all competitors

Product	Company	Stage	Hype Score
Crovalimab	Chugai Pharmaceutical	Phase 3	44
Crovalimab	Chugai Pharmaceutical	Phase 3	44
Ravulizumab	AstraZeneca	Pre-clinical	33
Eculizumab	AstraZeneca	Phase 3	40
Iptacopan	Novartis	Phase 3	44
Iptcaopan 200 mg	Novartis	Phase 3	47
Iptacopan	Novartis	Phase 3	47
MR13A9 + Placebo	Kissei Pharmaceutical	Phase 3	40
CCX168	Amgen	Phase 2	27
Stage I:HSK21542 0.05 μg/kg + Stage I:HSK21542 0.15 μg/kg + Stage I:HSK21542 0.30 μg/kg + Stage I:HSK21542 0.80 μg/kg + Stage II:HSK21542 0.3 μg/kg + Stage II:HSK21542 0.6 μg/kg	Haisco Pharmaceutical Group	Phase 2	35
Cemdisiran	Alnylam Pharmaceuticals	Phase 2	24
cemdisiran + Placebos	Alnylam Pharmaceuticals	Phase 2	24
nalbuphine HCl ER	Trevi Therapeutics	Phase 2/3	32
Nalbuphine HCL ER	Trevi Therapeutics	Phase 1	23
nalbuphine HCl ER tablets 60 mg BID + nalbuphine HCl ER tablets 120mg BID + Placebo tablets BID	Trevi Therapeutics	Phase 2/3	32